HD-OPM Archive
Topics › Low-carb, keto & carnivore

After reanalysis, Keto-CTA plaque growth still matches untreated metabolic syndrome

Louis Nervegna · Mar 02, 2026 · ♥ 9 reactions · 4 comments · original Facebook post
Low-carb, keto & carnivorePlaque, CAC & CT angiographyLDL, ApoB & lipid panel
AI summary & key facts

Louis argues the reanalyzed Keto-CTA plaque growth in the lean mass hyper-responder cohort is still as bad as that of people with untreated metabolic syndrome and prediabetes on a standard diet in the PARADIGM study, moving from 'horrible' to 'just plain bad'. PARADIGM used the same QAngio software as the reanalysis.

Even after re-analysis with QAngio software, the plaque growth in the Keto-CTA (LMHR) study is still bad [orange].

The plaque growth is as bad as people with untreated metabolic syndrome and prediabetes eating the standard American diet [gold], in the PARADIGM study.

After re-analysis, the results went from horrible [red] to just plain bad [orange].

Reference for graph:

mailchi.mpThe LDL Question: Reassessing the KETO-CTA Controversymailchi.mp

Quoted:

“The PARADIGM study is one of the most rigorous serial coronary imaging studies ever conducted. It tracked plaque progression in thousands of patients across 13 sites in 7 countries, using the same quantitative software — QAngio, made by Medis Medical Imaging — that was later used to reanalyze the KETO-CTA data.

In PARADIGM, metabolically healthy individuals with no risk factors [eating SAD diet] progressed at approximately 3.2 cubic millimeters of soft plaque per year [green]. Individuals with metabolic syndrome — pre-diabetic, often hypertensive, with poor lipid profiles — progressed at 5.6 cubic millimeters per year [gold].

The LMHR cohort progressed at 18.8 cubic millimeters per year [red]. In people selected specifically for optimal metabolic health. More than three times the metabolic syndrome rate. Even the reanalysis, which has not been peer reviewed, showed progression at 5.5 cubic millimeters per year in the LMHR group [orange].”

My note:

Compare the progressions in the quote above to people in the PARADIGM trial who were properly treated with statins [blue]. Their progression was only 0.5 cubic millimeters per year. They progressed at less than 1/10th the rate of people on a keto diet in the Keto-CTA study, even after re-analysis with QAngio software [orange].

For further comparison, a DASH diet plus statins produced a -39.5 cubic millimeter REGRESSION of soft plaque in the DISCO-CT trial. See these past posts:

↪ DISCO-CT: DASH diet plus statins reversed soft plaque by about 40 mm3 in a year

↪ Keto-CTA reanalysis: plaque progression still no better than the standard American diet.

#ketoctareanalysisHD #ketoctaHD #ketoctasummaryHD #paradigmHD

Research cited

← newer: Keto-CTA reanalysis: plaque progression still worse than theolder: New AHA risk calculator estimates 10- and 30-year heart dise →